News Image

DEXCOM INC (NASDAQ:DXCM) showing high EPS and FCF growth while beating expectations

By Mill Chart

Last update: Dec 13, 2023

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if DEXCOM INC (NASDAQ:DXCM) is suited for growth investing. Investors should of course do their own research, but we spotted DEXCOM INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Key Considerations for Growth Investors.

  • The Return on Equity (ROE) of DEXCOM INC stands at 16.62%, reflecting the company's strong profitability and effective utilization of shareholder equity. This metric signifies the company's ability to generate returns for its investors.
  • DEXCOM INC has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
  • DEXCOM INC has demonstrated strong 1-year revenue growth of 21.85%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
  • DEXCOM INC has achieved significant quarter-to-quarter (Q2Q) revenue growth of 26.69%, signaling its ability to capture market opportunities and drive top-line expansion. This growth underscores the company's effective execution and its potential for continued success.
  • DEXCOM INC has experienced notable growth in its operating margin over the past year, reflecting improved operational performance. This growth suggests the company's ability to generate higher profits from its core business activities.
  • With positive growth in its free cash flow (FCF) over the past year, DEXCOM INC showcases its ability to generate strong cash flows and maintain a solid financial position. This growth reflects the company's efficient utilization of capital and its commitment to long-term value creation.
  • The quarterly earnings of DEXCOM INC have shown a 78.57% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • The average next Quarter EPS Estimate by analysts was adjusted by 10.34%, reflecting the evolving market expectations for the company's EPS growth.
  • The quarterly earnings of DEXCOM INC have shown a 78.57% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • The earnings per share (EPS) growth of DEXCOM INC are accelerating: the current Q2Q growth of 78.57% is above the previous year Q2Q growth of 25.84%. Earnings momentum and acceleration are key for high growth systems.

How does the complete fundamental picture look for NASDAQ:DXCM?

As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to DXCM. DXCM was compared to 202 industry peers in the Health Care Equipment & Supplies industry. While DXCM has a great profitability rating, there are some minor concerns on its financial health. DXCM is growing strongly while it is still valued neutral. This is a good combination! These ratings could make DXCM a good candidate for growth investing.

For an up to date full fundamental analysis you can check the fundamental report of DXCM

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

DEXCOM INC

NASDAQ:DXCM (4/19/2024, 7:00:00 PM)

After market: 129.32 -1.39 (-1.06%)

130.71

-3.59 (-2.67%)

DXCM News

News Image2 days ago - Market News VideoFirst Week of December 20th Options Trading For DexCom (DXCM)
News Image3 days ago - Investor's Business DailyHow The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.

News Image4 days ago - InvestorPlace3 Weight-Loss ETFs to Profit From the Obesity Drug Boom

Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.

News Image8 days ago - InvestorPlaceDisruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape

This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024.

News Image8 days ago - Market News VideoSnowflake Larger Than S&P 500 Component DexCom
News Image9 days ago - Market News VideoFirst Week of DXCM May 31st Options Trading
News Image9 days ago - Investor's Business DailyWhy Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?

News Image10 days ago - ChartmillWhy NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.

Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout.

News Image10 days ago - InvestorPlaceNasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In

DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading.

News Image10 days ago - InvestorPlace3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments

News Image12 days ago - Investor's Business DailyDexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating

The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.

News Image13 days ago - The Motley Fool2 Growth Stocks to Buy Hand Over Fist in April

These healthcare companies' target markets substantially overlap.

DXCM Links
Follow us for more